Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM3E2IY)

Drug Name
225Ac-labelled aCD38 Drug Info
Indication
Disease Entry ICD 11 Status REF
Multiple myeloma 2A83 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM3E2IY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclic ADP-ribose hydrolase 1 (CD38) TTPURFN CD38_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cyclic ADP-ribose hydrolase 1 (CD38) DTT CD38 6.658 6.115 5.04 6.932
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Bone marrow
The Studied Disease Multiple myeloma [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cyclic ADP-ribose hydrolase 1 (CD38) DTT CD38 8.33E-02 0.22 0.69
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02998047) A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma. U.S. National Institutes of Health.
2 Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.